San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
The unofficial theme of Sanford Burnham Prebys’ 10th annual Rare Disease Day symposium can be summarized in one word: hope.
This year’s event focused on rare bone conditions and cancer, including a condition called multiple hereditary exostoses (MHE)… […]
Armed with wiggly worms and striped zebrafish, on Saturday, March 2, more than 20 volunteers from Sanford Burnham Prebys helped kids and their families learn about the power of DNA at the San Diego Festival of Science & Engineering’s EXPO Day.
On… […]
CLAREMONT, Calif., March 25, 2019 /PRNewswire/ — Researchers have found multiple applications for the CRISPR (Clustered Regularly Interspersed Short Palindromic Repeats) gene editing technology since it came into use by the scientific community. Ke… […]
Charge Density Mapping Transforms Understanding of Atrial Arrhythmias
CARLSBAD, Calif., March 25, 2019 /PRNewswire/ — Acutus Medical today announced the publication of “High Resolution Non-Contact Charge Density Mapping of Endocardial Activation” in… […]
SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences (APHB), a clinical-stage biotech company focused on bacteriophage therapeutics, announced 4Q & 2018 full year financial results. […]
CARLSBAD, Calif. & BRISBANE, Australia–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ASBrS19?src=hash" target="_blank"gt;#ASBrS19lt;/agt;–PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Mee… […]
LA JOLLA—Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed medication for major depressive disorder (MDD), yet scientists still do not understand why the treatment does not work in nearly thirty percent of patients with M… […]
LA JOLLA—(March 22, 2019) Similar to the dozens of Sherpas that guide hikers up treacherous Himalayan mountains to reach a summit, the nervous system relies on elaborate timing and location of guidance cues for neuronal axons—threadlike projections—to … […]
Turning Point Therapeutics, which is developing targeted cancer drugs for patients whose tumors resist other precision therapies, has outlined plans for an IPO. The company, which started operations in 2014, has raised nearly $148 million since incepti… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
